GSK plc (FRA:GS71)
Germany
· Delayed Price · Currency is EUR 16.37
-0.80 (-4.63%)
Last updated: May 7, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| HIV | 7.09B |
Log In |
Log In |
Log In |
Log In |
| HIV Growth | 10.01% |
Log In |
Log In |
Log In |
Log In |
| Meningitis | 1.44B |
Log In |
Log In |
Log In |
Log In |
| Meningitis Growth | 14.05% |
Log In |
Log In |
Log In |
Log In |
| Influenza | 408.00M |
Log In |
Log In |
Log In |
Log In |
| Influenza Growth | -19.05% |
Log In |
Log In |
Log In |
Log In |
| Established Vaccines | 3.34B |
Log In |
Log In |
Log In |
Log In |
| Established Vaccines Growth | 2.24% |
Log In |
Log In |
Log In |
Log In |
| Vaccines | 9.14B |
Log In |
Log In |
Log In |
Log In |
| Vaccines Growth | -7.36% |
Log In |
Log In |
Log In |
Log In |
| Shingles | 3.36B |
Log In |
Log In |
Log In |
Log In |
| Shingles Growth | -2.38% |
Log In |
Log In |
Log In |
Log In |
| Oncology | 1.41B |
Log In |
Log In |
Log In |
Log In |
| Oncology Growth | 92.89% |
Log In |
Log In |
Log In |
Log In |
| Immuno-Inflammation, Respiratory and Other | 3.30B |
Log In |
Log In |
Log In |
Log In |
| Immuno-Inflammation, Respiratory and Other Growth | 9.06% |
Log In |
Log In |
Log In |
Log In |
| Specialty Medicines | 11.81B |
Log In |
Log In |
Log In |
Log In |
| Specialty Medicines Growth | 15.29% |
Log In |
Log In |
Log In |
Log In |
| Respiratory | 7.21B |
Log In |
Log In |
Log In |
Log In |
| Respiratory Growth | 5.68% |
Log In |
Log In |
Log In |
Log In |
| Other General Medicines | 3.22B |
Log In |
Log In |
Log In |
Log In |
| Other General Medicines Growth | -5.30% |
Log In |
Log In |
Log In |
Log In |
| General Medicines | 10.43B |
Log In |
Log In |
Log In |
Log In |
| General Medicines Growth | 2.04% |
Log In |
Log In |
Log In |
Log In |
| Total Commerical Operations | 31.38B |
Log In |
Log In |
Log In |
Log In |
| Total Commerical Operations Growth | 3.46% |
Log In |
Log In |
Log In |
Log In |
| Total Consumer Healthcare | - |
Log In |
Log In |
Log In |
Log In |
| Pandemic | - |
Log In |
Log In |
Log In |
Log In |
| Pandemic Growth | - |
Log In |
Log In |
Log In |
Log In |
| Pandemic Vaccines | - |
Log In |
Log In |
Log In |
Log In |
| Pandemic Vaccines Growth | - |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Commercial Operations Segment Profit | 15.34B |
Log In |
Log In |
Log In |
Log In |
| Commercial Operations Segment Profit Growth | 4.63% |
Log In |
Log In |
Log In |
Log In |
| Research & Development Segment Profit | -5.85B |
Log In |
Log In |
Log In |
Log In |
| Research & Development Segment Profit Growth | 4.24% |
Log In |
Log In |
Log In |
Log In |
| Consumer Healthcare Segment Profit | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| US Revenue | 16.38B |
Log In |
Log In |
Log In |
Log In |
| US Revenue Growth | 3.57% |
Log In |
Log In |
Log In |
Log In |
| Europe | 6.67B |
Log In |
Log In |
Log In |
Log In |
| Europe Growth | 1.55% |
Log In |
Log In |
Log In |
Log In |
| International | 8.33B |
Log In |
Log In |
Log In |
Log In |
| International Growth | 4.81% |
Log In |
Log In |
Log In |
Log In |